Literature DB >> 2878177

Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon.

B Eriksson, K Oberg, G Alm, A Karlsson, G Lundqvist, T Andersson, E Wilander, L Wide.   

Abstract

22 patients with advanced malignant endocrine pancreatic tumours were treated with human leucocyte interferon 3-6 X 10(6) IU per day. Objective responses (more than 50% reduction in tumour markers or tumour size) were seen in 7/7 with watery diarrhoea/hypokalaemia/achlorhydria syndrome, 3/4 with the Zollinger-Ellison syndrome, 6/9 with "non-functioning" tumours, and 1 with a mixed tumour mainly producing somatostatin. The median duration of response was 8.5 months, and all responders improved clinically. Adverse effects seemed more tolerable than those of cytotoxic treatment.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2878177     DOI： 10.1016/s0140-6736(86)91435-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  14 in total

Review 1.  Interferon for treatment: the dust settles.

Authors:  D Galvani; S D Griffiths; J C Cawley
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-04

Review 2.  Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options.

Authors:  H N Nguyen; B Backes; F Lammert; J Wildberger; R Winograd; N Busch; H Rieband; S Matern
Journal:  Dig Dis Sci       Date:  1999-06       Impact factor: 3.199

3.  Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs.

Authors:  M L Fjällskog; A Sundin; J E Westlin; K Oberg; E T Janson; B Eriksson
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

4.  Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years.

Authors:  Henrik Kindmark; Anders Sundin; Dan Granberg; Kristina Dunder; Britt Skogseid; Eva Tiensuu Janson; Staffan Welin; Kjell Oberg; Barbro Eriksson
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

Review 5.  Medical treatment of gastrinomas.

Authors:  Christoph J Auernhammer; Burkhard Göke
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 6.  Pancreatic vipomas: spectrum of presentation and evolution of diagnostic and therapeutic modalities.

Authors:  S F Leavey; H Holloway; M G Courtney; B E Lane; D Royston; K D Buchanan; J F Fielding
Journal:  Ir J Med Sci       Date:  1995-01       Impact factor: 1.568

Review 7.  [Drug therapy of endocrine neoplasms. Part II: Malignant gastrinomas, insulinomas, glucagonomas, carcinoids and other tumors].

Authors:  M Schott; W A Scherbaum; J Feldkamp
Journal:  Med Klin (Munich)       Date:  2000-02-15

Review 8.  Neuroendocrine metastases of the liver.

Authors:  I Ihse; B Persson; S Tibblin
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

Review 9.  The effect of Zollinger-Ellison syndrome and neuropeptide-secreting tumors on the stomach.

Authors:  J R Pisegna
Journal:  Curr Gastroenterol Rep       Date:  1999-12

10.  Prospective comparative study of ability of MR imaging and other imaging modalities to localize tumors in patients with Zollinger-Ellison syndrome.

Authors:  J R Pisegna; J L Doppman; J A Norton; D C Metz; R T Jensen
Journal:  Dig Dis Sci       Date:  1993-07       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.